Climara Patch Dosing Schedule
No, Climara is not a once-weekly patch—it is applied once weekly, meaning you replace it every 7 days, not that it lasts only one week. The patch is designed for continuous wear over a full 7-day period before replacement 1.
Application Schedule
A new Climara system should be applied weekly during a 28-day cycle 1. This means:
- Apply the patch and wear it continuously for 7 days
- Remove and replace with a new patch on the same day each week
- The patch delivers estradiol continuously throughout the entire 7-day wearing period
Key Prescribing Details
Dosing Formulations
The standard Climara transdermal system delivers 0.045 mg of estradiol per day (when combined with levonorgestrel in Climara Pro), though other strengths exist delivering 25,50, or 75 micrograms/day depending on the formulation 1, 2.
Application Site
- Apply to the lower abdomen on smooth, clean, dry, non-oily skin 1
- Rotate application sites with at least one week between applications to the same location 1
- The buttocks are an acceptable alternative site and may provide 117-125% bioavailability compared to abdominal application, potentially advantageous for women experiencing end-of-week breakthrough symptoms 3
- Avoid the waistline where tight clothing may dislodge the patch 1
- Never apply to or near the breasts 1
Pharmacokinetic Profile
The patch maintains sustained premenopausal estradiol levels throughout the 7-day application period 3, 2. After patch removal, serum estradiol concentrations decline rapidly with a mean terminal half-life of approximately 3 hours 1.
Common Pitfall
Accidental same-site reapplication does not cause hormone accumulation 4, though site rotation remains recommended to minimize dermatologic reactions.
Clinical Context from Guidelines
Transdermal estradiol preparations, including weekly patches, have similar efficacy to oral estrogen therapy for reducing menopausal symptoms 5. The primary advantage is avoiding first-pass hepatic metabolism, making transdermal formulations preferable for women with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or gallbladder disease history 5.